Parexel and Datavant partner to link to real-world data

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/solarseven)
(Image: Getty/solarseven)

Related tags: Real world data, Real world evidence, Data, Data management, data model, Clinical trial

Parexel and Datavant have partnered to boost clinical study design and operations through the generation of real-world evidence.

Parexel, a global biopharmaceutical company, will work with Datavant to link health care data from real-world and clinical study data sources. The partnership will tap Datavant’s technology which links traditional health care data sources like electronic medical records (EMRs), claims, and diagnostics.

Jason Martin, corporate vice president of global data operations at Parexel told us, “With all of this data available, there is an opportunity to have a single longitudinal healthcare view of an individual, however much of these patient health care utilization data and health records are often spread across many sources without a common index to link up patient records.”

Martin said, “Parexel chose Datavant because [its] solution enables the connection of patient datasets across disparate sources through a distributed indexing approach while protecting the privacy of patients.”

Parexel has a four-pillared real-world data approach and this partnership builds upon this approach to integrate data access, technologies, and capabilities.

The Economist Intelligence Unit (EIU) released a study​,​ commissioned by Parexel, that stated real world data played a role in more efficient drug development. The likelihood of launch increased by 21% for trials using real world data. “Through the Economist Intelligence Unit research, it’s clear that real-world data plays a significant role in the acceleration of clinical study timelines and answering previously elusive clinical research questions,”​ said Martin.

We reported that Parexel recently opened a new Innovation Center​ after the EIU report also stated that patient-centric clinical trials recruited participants almost half the time and the drugs in these trials were 19% more likely to be launched. 

Related news

Show more

Related products

show more

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us


View more